865P - A cytokine and angiogenic factor (CAF) analysis in plasma in testicular germ cell tumor patients

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Germ Cell Tumours
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Michal Mego
Authors M. Mego1, D. Cholujova2, P. Gronesova2, M. Pastorek2, V. Miskovska'3, J. Obertova4, V. Usakova5, D. Ondrus3, S. Spanik6, J. Mardiak4
  • 1National Cancer Institute, Slovakia, 83310 - Bratislava/SK
  • 2Cancer Immunology, Cancer Research Institute, Slovak Academy of Sciences, 83310 - Bratislava/SK
  • 3Medical Oncology, St. Elisabeth Cancer Institute, SK-81250 - Bratislava/SK
  • 4Medical Oncology, National Cancer Institute, Slovakia, 83310 - Bratislava/SK
  • 5Clinical Oncology, St. Elisabeth Cancer Institute, SK-81250 - Bratislava/SK
  • 6St. Elisabeth Cancer Institute, SK-81250 - Bratislava/SK



Testicular germ-cell tumours (TGCTs) represent a model for the cure of cancer. Nonetheless, a small proportion of patients develop disease recurrence. We investigated cytokines and angiogenic factors (CAFs) in patients with TGCTs. We aimed to link the CAF profile to PFS and select candidate predictive and prognostic markers for further study.


In this ongoing translational study, plasma from 55 patients with TGCTs was collected. The concentrations of 51 plasma CAFs were measured pretreatment (n = 47) and on day 22 (n = 30) using multiplex bead arrays (Human Group I and II cytokine panels and TGF beta by Bio-Plex 200 system (Bio-Rad Laboratories, Hercules, CA). We investigated the association between baseline levels of CAFs and clinico-pathological variables.


We observed elevated level of transforming growths factor beta1 (TGF-b1), IL-2Ra, CXCL9, CXCL10, IFN-gama, macrophage inflammatory protein-1b (MIP-1b), and platelet-derived growth factor-BB (PDGF-BB) in seminoma patients compared to non-seminoma. Patients with poor prognosis according to IGCCCG have elevated pretreatment level of beta-nerve growth factor (NGF-b) and stromal cell-derived factor-1 (SDF-1a) compared to patients with good/intermediate prognosis. Patients with metastatic disease had elevated pretreatment level of stem cell growth factor beta (SCGF-b) and PDGF-BB compared to patients with stage I disease.


Using CAF profiling, we revealed differences in subgroups of TGCTs patients. We suggest that this platform may provide valuable insights into TGCTs biology, and could be useful in identification of new therapeutic targets.


All authors have declared no conflicts of interest.